Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Rating of “Moderate Buy” from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $99.17.

A number of research analysts recently weighed in on LNTH shares. B. Riley lifted their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Truist Financial boosted their target price on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. Mizuho raised their price target on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 3rd. JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd.

Lantheus Trading Down 2.0 %

Shares of LNTH stock opened at $74.51 on Thursday. The firm’s 50-day simple moving average is $63.16 and its 200-day simple moving average is $62.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. Lantheus has a 1-year low of $50.20 and a 1-year high of $100.85. The firm has a market cap of $5.16 billion, a P/E ratio of 11.38 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. As a group, equities analysts forecast that Lantheus will post 5.96 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. Over the last three months, insiders sold 94,545 shares of company stock worth $6,169,936. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of Lantheus

Several hedge funds have recently made changes to their positions in the stock. Tucker Asset Management LLC lifted its stake in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 282 shares during the last quarter. UMB Bank n.a. lifted its position in Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in Lantheus by 97.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the period. Principal Securities Inc. bought a new position in Lantheus in the 4th quarter worth about $28,000. Finally, Covestor Ltd increased its stake in shares of Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 203 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.